Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Mastocytosis, Systemic

• Study of BLU-263 in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies
• A Phase 1 Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
• (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
• Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients
• (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
• (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
• Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
• (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
• (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
• Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis
• GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
• A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
• (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
• Treatment of Indolent Systemic Mastocytosis With PA101
• Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis
• Tagraxofusp (SL-401) in Patients With CMML or MF
• Midostaurin in Indolent Systemic Mastocytosis
• Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
• Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
• Imatinib in KIT-negative Systemic Mastocytosis
• Evaluation of Response of Dasatinib to Treat Mastocytosis
• Obatoclax for Systemic Mastocytosis
• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
• Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
• Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
• Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
• Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
• Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
• Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
• A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies